Publication bias refers to the systematic distortion of the scientific literature that occurs when studies with positive or statistically significant results are published more frequently than studies with negative, neutral, or inconclusive findings. This bias distorts the overall picture of the state of research and can lead to false conclusions about the efficacy and safety of medicinal products or therapeutic procedures. <\/p>\n
Publication bias arises at multiple levels of the research process. Authors and researchers tend not to submit studies with non-significant results for publication\u2014a phenomenon known as the “file drawer problem.” At the same time, journals reject such manuscripts more frequently than studies with clear positive results. Sponsors of clinical trials can contribute to bias through selective reporting by withholding unfavorable results. The timing of publication also plays a role: studies with significant results are published more quickly and in journals with higher impact factors, leading to time-lag bias. <\/p>\n
Other forms of related bias include outcome reporting bias (selective reporting of individual endpoints within a study), language bias (preferential publication of English-language results), and citation bias (more frequent citation of positive studies). All these mechanisms amplify the overall effect of publication bias on the cumulative evidence base. <\/p>\n
The consequences of publication bias are substantial for evidence-based medicine. Systematic reviews and meta-analyses based on the available published literature systematically overestimate the effect size of an intervention when negative studies are missing. This can lead to treatments appearing more effective than they actually are. In regulatory assessment by authorities such as the EMA or BfArM, all clinical trial results\u2014both positive and negative\u2014are therefore submitted as part of the Clinical Study Report (CSR), regardless of their publication in journals. <\/p>\n
Publication bias is particularly critical in the assessment of drug safety. If studies with adverse events or negative safety signals are missing from the literature, risks can be systematically underestimated. The EU pharmacovigilance system therefore requires marketing authorization holders to report all safety data in full, regardless of their publication status. <\/p>\n
Various methods are available for identifying publication bias in systematic reviews and meta-analyses. The funnel plot is the most commonly used graphical tool: missing studies in the asymmetric area of the funnel diagram indicate publication bias. Statistical tests such as the Egger test or Begg test are used as supplements to formally examine the asymmetry. <\/p>\n
The trim-and-fill method estimates the number of missing studies and adjusts the pooled effect estimate accordingly. The fail-safe N value (according to Rosenthal) indicates how many unpublished null-result studies would have to exist to statistically eliminate the observed overall effect. However, these methods have limitations: they require a sufficient number of available studies and cannot completely eliminate bias, only quantify it. <\/p>\n
The most effective countermeasure against publication bias is the prospective registration of clinical trials before recruitment begins. EU Regulation 536\/2014 (Clinical Trials Regulation, CTR) requires sponsors to register all clinical trials in the EU Clinical Trials Register (EUCTR) or the Clinical Trials Information System (CTIS). The ICH Guideline E17 and the WHO ICTRP registry additionally require timely publication of study results. <\/p>\n
Mandatory result reporting deadlines (in the EU: 12 months after study completion, 6 months for pediatric studies) are intended to ensure that negative results are also made publicly available. For full-service CROs such as mediconomics, this means supporting sponsors in complete and timely registration and result reporting in CTIS. The European Public Assessment Report (EPAR) procedure of the EMA additionally makes study results publicly accessible through the Clinical Study Report sharing program. <\/p>\n
In the context of study planning and analysis, addressing publication bias is relevant for several professional groups. Biostatisticians must plan methods for detecting and correcting publication bias when designing meta-analyses and systematic reviews. Clinical monitors and data managers contribute to reducing outcome reporting bias through complete and transparent documentation of all study endpoints\u2014including exploratory and secondary endpoints. <\/p>\n
The study plan (protocol) defines all primary and secondary endpoints in a binding manner. Subsequent changes to endpoint definition or hierarchy (outcome switching) are considered serious protocol deviations and must be documented as an amendment. The Data Safety Monitoring Board (DSMB) has the responsibility to report safety signals regardless of their statistical significance. <\/p>\n
What is the difference between publication bias and outcome reporting bias?<\/strong><\/p>\n Publication bias refers to the selective publication of entire studies\u2014preferentially those with positive results. Outcome reporting bias, on the other hand, concerns the selective reporting of individual endpoints within a published study, where statistically significant or favorable results are highlighted and other endpoints are suppressed. Both forms of bias can occur together and mutually reinforce their impact on the evidence base. <\/p>\n How does EU regulation protect against publication bias?<\/strong><\/p>\n EU Regulation 536\/2014 requires sponsors to register all clinical trials in CTIS and to publish study results within specified deadlines. Additionally, the EMA requires submission of all clinical data as part of the marketing authorization procedure\u2014regardless of whether the studies have been published. Through the Clinical Study Data Sharing program, sponsors are required to make anonymized patient data accessible upon request. <\/p>\n How does publication bias influence the interpretation of meta-analyses?<\/strong><\/p>\n Meta-analyses based on unpublished negative studies typically overestimate the treatment effect. Funnel plot asymmetry and statistical tests such as the Egger test enable assessment of the extent of bias. The Cochrane guidelines recommend explicitly addressing the risk of publication bias in every systematic review and conducting sensitivity analyses where appropriate to examine the robustness of the conclusions. <\/p>\n Publication bias refers to the systematic distortion of the scientific literature that occurs when studies with positive or statistically significant results are published more frequently than studies with negative, neutral, or inconclusive findings. This bias distorts the overall picture of the state of research and can lead to false conclusions about the efficacy and safety […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6758","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6758\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6758"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n